Book contents
- Stahl’s Self-Assessment Examination in Psychiatry
- Stahl’s Self-Assessment Examination in Psychiatry
- Copyright page
- Contents
- Introduction/Preface
- CME/CE Information
- 1 ADHD and Its Treatment
- 2 Anxiety/Stress Disorders and Their Treatment
- 3 Basic Neuroscience and Pharmacological Concepts
- 4 Bipolar Disorder and Its Treatment
- 5 Chronic Neuropathic Pain and Its Treatment
- 6 Dementia and Its Treatment
- 7 Psychosis and Its Treatment
- 8 Sleep/Wake Disorders and Their Treatment
- 9 Substance Use/Impulsive-Compulsive Disorders and Their Treatment
- 10 Unipolar Depression and Its Treatment
- Index
- References
This chapter is part of a book that is no longer available to purchase from Cambridge Core
5 - Chronic Neuropathic Pain and Its Treatment
Book contents
- Stahl’s Self-Assessment Examination in Psychiatry
- Stahl’s Self-Assessment Examination in Psychiatry
- Copyright page
- Contents
- Introduction/Preface
- CME/CE Information
- 1 ADHD and Its Treatment
- 2 Anxiety/Stress Disorders and Their Treatment
- 3 Basic Neuroscience and Pharmacological Concepts
- 4 Bipolar Disorder and Its Treatment
- 5 Chronic Neuropathic Pain and Its Treatment
- 6 Dementia and Its Treatment
- 7 Psychosis and Its Treatment
- 8 Sleep/Wake Disorders and Their Treatment
- 9 Substance Use/Impulsive-Compulsive Disorders and Their Treatment
- 10 Unipolar Depression and Its Treatment
- Index
- References
Summary
A 34-year-old woman with fibromyalgia, generalized anxiety disorder, and depression is currently taking several psychotropic medications, including alprazolam, duloxetine, hydrocodone/acetaminophen, and pregabalin. She continues to have residual pain, anxiety, and mood symptoms. Her clinician is considering simplifying her medication regimen and plans to discontinue the medication with the least evidence of efficacy for her disorders. Which of the following should be discontinued?
Information
- Type
- Chapter
- Information
- Stahl's Self-Assessment Examination in PsychiatryMultiple Choice Questions for Clinicians, pp. 153 - 178Publisher: Cambridge University PressPrint publication year: 2022
References
References
Ballantyne, JC, Shin, NS. Efficacy of opioids for chronic pain: a review of the evidence. Clin J Pain 2008;24:469–78.Google Scholar
References
Kumar, A, Kaur, H, Singh, A. Neuropathic pain models caused by damage to central or peripheral nervous system. Pharmacol Rep 2018;70(2):206–16.Google Scholar
Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 9)CrossRefGoogle Scholar
References
Kumar, A, Kaur, H, Singh, A. Neuropathic pain models caused by damage to central or peripheral nervous system. Pharmacol Rep 2018;70(2):206–16.Google Scholar
Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 9)CrossRefGoogle Scholar
References
Aydede, M, Shriver, A. Recently introduced definition of “nociplastic pain” by the International Association for the Study of Pain needs better formulation. Pain 2018;159:1176–7.CrossRefGoogle Scholar
Kosek, E, Cohen, M, Baron, R et al. Do we need a third mechanistic descriptor for chronic pain states? Pain 2016;157:1382–6.Google Scholar
Kumar, A, Kaur, H, Singh, A. Neuropathic pain models caused by damage to central or peripheral nervous system. Pharmacol Rep 2018;70(2):206–16.CrossRefGoogle ScholarPubMed
References
Belinskaia, DA, Belinskaia, MA, Barygin, OI, Vanchakova, NP, Shestakova, NN. Psychotropic drugs for the management of chronic pain and itch. Pharmaceuticals (Basel) 2019;12(2):99.CrossRefGoogle ScholarPubMed
Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 9)CrossRefGoogle Scholar
References
Dooley, DJ, Taylor, CP, Donevan, S, Feltner, D. Ca2+ channel alpha 2 delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci 2007;28:75–82.Google Scholar
Jensen, TS. Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain 2002;6(Suppl A):61–8.Google Scholar
Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 9)Google Scholar
References
Fernandes, V, Sharma, D, Vaidya, S et al. Cellular and molecular mechanisms driving neuropathic pain: recent advancements and challenges. Expert Opin Ther Targets 2018;22(2):131–42.Google Scholar
Kumar, A, Kaur, H, Singh, A. Neuropathic pain models caused by damage to central or peripheral nervous system. Pharmacol Rep 2018;70(2):206–16.CrossRefGoogle ScholarPubMed
Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 9)Google Scholar
References
Stahl, SM. Stahl’s essential psychopharmacology: the prescriber’s guide, seventh edition. New York, NY: Cambridge University Press; 2020.CrossRefGoogle Scholar
Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 9)CrossRefGoogle Scholar
References
Stahl, SM. Case studies: Stahl’s essential psychopharmacology. New York, NY: Cambridge University Press; 2011.Google Scholar
Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 9)CrossRefGoogle Scholar
References
Atkinson, JH, Slater, MA, Capparelli, EV et al. Efficacy of noradrenergic and serotonergic antidepressants in chronic back pain: a preliminary concentration-controlled trial. J Clin Psychopharmacol 2007;27:135–42.CrossRefGoogle ScholarPubMed
Scholz, BA, Hammonds, CL, Boomershine, CS. Duloxetine for the management of fibromyalgia syndrome. J Pain Res 2009;2:99–108.Google ScholarPubMed
Stahl, SM. Stahl’s essential psychopharmacology: the prescriber’s guide, seventh edition. New York, NY: Cambridge University Press; 2020.CrossRefGoogle Scholar
References
Baldo, BA, Rose, MA. The anaesthetist, opioid analgesic drugs, and serotonin toxicity: a mechanistic and clinical review. Br J Anaesth 2020;124(1):44–62.CrossRefGoogle ScholarPubMed
Francescangeli, J, Karamchandani, K, Powell, M, Bonavia, A. The serotonin syndrome: from molecular mechanisms to clinical practice. Int J Mol Sci 2019;20(9):2288.Google Scholar
US Food and Drug Administration. FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. March 22, 2016.Google Scholar
References
Atkinson, JH, Slater, MA, Capparelli, EV et al. Efficacy of noradrenergic and serotonergic antidepressants in chronic back pain: a preliminary concentration-controlled trial. J Clin Psychopharmacol 2007;27:35–142.CrossRefGoogle ScholarPubMed
Belinskaia, DA, Belinskaia, MA, Barygin, OI, Vanchakova, NP, Shestakova, NN. Psychotropic drugs for the management of chronic pain and itch. Pharmaceuticals (Basel) 2019;12(2):99.Google Scholar
Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 9)CrossRefGoogle Scholar
Accessibility standard: Unknown
Why this information is here
This section outlines the accessibility features of this content - including support for screen readers, full keyboard navigation and high-contrast display options. This may not be relevant for you.Accessibility Information
Accessibility compliance for the HTML of this chapter is currently unknown
and may be updated in the future.